Advertisement
Australia markets closed
  • ALL ORDS

    8,118.30
    -1.90 (-0.02%)
     
  • AUD/USD

    0.6661
    -0.0008 (-0.13%)
     
  • ASX 200

    7,848.10
    -3.60 (-0.05%)
     
  • OIL

    78.07
    -0.59 (-0.75%)
     
  • GOLD

    2,418.40
    -7.50 (-0.31%)
     
  • Bitcoin AUD

    105,016.18
    -1,529.32 (-1.44%)
     
  • CMC Crypto 200

    1,499.84
    -26.58 (-1.74%)
     

Investors in Actinogen Medical (ASX:ACW) have unfortunately lost 53% over the last year

Actinogen Medical Limited (ASX:ACW) shareholders will doubtless be very grateful to see the share price up 50% in the last quarter. But that's small comfort given the dismal price performance over the last year. Specifically, the stock price slipped by 55% in that time. So the bounce should be viewed in that context. You could argue that the sell-off was too severe.

It's worthwhile assessing if the company's economics have been moving in lockstep with these underwhelming shareholder returns, or if there is some disparity between the two. So let's do just that.

Check out our latest analysis for Actinogen Medical

Because Actinogen Medical made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.

ADVERTISEMENT

In the last twelve months, Actinogen Medical increased its revenue by 3.2%. That's not a very high growth rate considering it doesn't make profits. Without profits, and with revenue growth sluggish, you get a 55% loss for shareholders, over the year. Like many holders, we really want to see better revenue growth in companies that lose money. When a stock falls hard like this, it can signal an over-reaction. Our preference is to wait for a fundamental improvements before buying, but now could be a good time for some research.

The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).

earnings-and-revenue-growth
earnings-and-revenue-growth

You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic.

A Different Perspective

Investors in Actinogen Medical had a tough year, with a total loss of 53%, against a market gain of about 14%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 7% per year over five years. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. It's always interesting to track share price performance over the longer term. But to understand Actinogen Medical better, we need to consider many other factors. Take risks, for example - Actinogen Medical has 7 warning signs (and 2 which are a bit concerning) we think you should know about.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Australian exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.